Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mirikizumab - Eli Lilly and Company

Drug Profile

Mirikizumab - Eli Lilly and Company

Alternative Names: IL-23p19 antibody - Eli Lilly and Company; LY 3074828; Miri - Eli Lilly and Company

Latest Information Update: 17 May 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Interleukin-23 subunit p19 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Crohn's disease; Ulcerative colitis
  • Discontinued Plaque psoriasis

Most Recent Events

  • 06 May 2021 Eli Lilly and Company withdraws IIIb LUCENT-ACT trial in Ulcerative Colitis (Treatment-experienced) (IV) (SC) prior to enrolment secondary to a business decision (NCT04469062) (EudraCT2019-001653-99)
  • 27 Apr 2021 Discontinued - Phase-I for Plaque psoriasis (In volunteers) in USA (IV)
  • 27 Apr 2021 Discontinued - Phase-I for Plaque psoriasis in Canada (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top